Skip to main content
. 2020 Feb 7;15(2):e0228486. doi: 10.1371/journal.pone.0228486

Table 2. High output cardiac failure group summarized data.

Baseline 3 ms 6 ms 12 ms 18 ms 24 ms Comments
Pt 1: F 47 y/o. CI 5.6 6.3 4.3 4.3 Re-induction after 3 years (bleeding). Died due to a septic shock almost 4 years after enrollment while on LT list
Co 8.6 9.2 6.7 6.7
PSP 53 44 35
Hb 9.1 12.1 9.3 9.8 7
Bvz 6 2
Baseline 3 ms 6 ms 12 ms 18 ms 24 ms Comments
Pt 2: F 53 y/o. CI 4.5 4 Died due to pneumonia about 20 months after enrollment
Co 7.5 6.2
PSP 45 60 28 45
Hb 12.4 13.5 12.8 12.5
Bvz 6
Baseline 3 ms 6 ms 12 ms 18 ms 24 ms Comments
Pt 3: F 36 y/o. CI 6.2 3.1 3.1 4.9 LT 2 years after enrollment. Alive
Co 9.3 4.6 4.1 7.7
PSP 36 24 22
Hb 7 8.7 7.5 7.6
Bvz 6 3
Baseline 3 ms 6 ms 12 ms 18 ms 24 ms Comments
Pt 4: M 45 y/o CI 4.1 3.4 5.6 LT 1 year after enrollment. Alive
Co 8 6.3 10
PSP 65 79 121 62
Hb 9.3 10.7 10.6 8.4 8.5 9.3
Bvz 6
Baseline 3 ms 6 ms 12 ms 18 ms 24 ms Comments
Pt 5: F 81 y/o. CI Died due to cardiogenic shock about 4 days after receiving first dose of bevacizumab
Co
PSP 72
Hb 10.4
Bvz 1
Baseline 3 ms 6 ms 12 ms 18 ms 24 ms Comments
Pt 6: M 72 y/o CI 4.5 Died due to pneumonia after receiving 2 doses of bevacizumab
Co 9.2
PSP 71
Hb 8
Bvz 2
Baseline 3 ms 6 ms 12 ms 18 ms 24 ms Comments
Pt 7: M 61 y/o CI 3.8 Alive, recently enrolled
Co 6.7
PSP 65
Hb 8.4
Bvz 1

Pt: patient. M: male. F: female. CI: cardiac index L/m2/min. Co: cardiac output L/min. PSP: pulmonary systolic pressure mmHg. Hb: hemoglobin g/dl. Bvz: number of bevacizumab applications. LT: Liver transplantation.